Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

Peter D Zang; Neal S Chawla; Regina Barragan-Carrillo; Alex Chehrazi-Raffle; Abhishek Tripathi; Sumanta K Pal; Tanya B Dorff

doi:10.1001/jamaoncol.2023.6817

Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer and Response to Checkpoint Inhibition

JAMA Oncol. 2024 Apr 1;10(4):531-532. doi: 10.1001/jamaoncol.2023.6817.

Authors

Peter D Zang¹, Neal S Chawla¹, Regina Barragan-Carrillo¹, Alex Chehrazi-Raffle¹, Abhishek Tripathi¹, Sumanta K Pal¹, Tanya B Dorff¹

Affiliation

¹ Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California.

PMID: 38329743
PMCID: PMC10853862 (available on 2025-02-08)
DOI: 10.1001/jamaoncol.2023.6817

No abstract available

Plain language summary

This single-center cohort study assesses the association of tumor mutational burden status in patients with metastatic castration-resistant prostate cancer and response to immune checkpoint inhibitor therapy.

MeSH terms

Biomarkers, Tumor
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

Biomarkers, Tumor